Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…
ractigenMarch 3, 2023
